

Institutional Review Board (IRB) statement


“Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy” entitled by Yamashita K et al. was assessed for publication disclosure by the Ethics Committee of the Kitasato University School of Medicine.

This study is a retrospective study investigating clinical features of 172 advanced gastric cancer patients who were treated between 2000 and 2010 in the department of surgery, the Kitasato University School of Medicine. The patients were treated by standard curative gastrectomy and postoperative S1 adjuvant chemotherapy. Medical data is collected retrospectively, and analyzed, in which the patients who were being registered in the phase III clinical trial designated as ACTS-GC (adjuvant chemotherapy study-gastric cancer) were included between 2000 and 2006. Since 2007, S1 chemotherapy was administered as a standard treatment in the context of the approved official use in Japan. In the publication, clinical features of the patients including prognosis were retrospectively investigated and disclosed.

The Ethics Committee of the Kitasato University School of Medicine approved the appropriate disclosure of the retrospective investigational contents for publication.

Toshiyuki Miyashita
Chairman of the IRB Office
Kitasato University School of Medicine

Toshiyuki Miyashita



1/23/2016